An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Official Title

A Phase Illb/IV Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer


A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

Trial Description

Primary Outcome:

  • Number of participants who experience high grade AEs (Adverse Events)
  • Percentage of participants who experience high grade AEs
Secondary Outcome:
  • Progression-free survival (PFS)
  • Objective Response Rate (ORR)
  • Duration of Response (DOR)
  • Functional Assessment of Cancer Therapy-Lung (FACT-L)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society